Protea Biosciences releases mass spectrometry imaging data for characterizing 3D microtissues
Schlieren, Switzerland and Morgantown, West Virginia, November 5, 2014 – Data presented at InSphero user group meeting by Dr. Erin Seeley. PDF Version
Protea Biosciences Group, Inc. (OTCQB:PRGB) and InSphero AG jointly announced today that Protea has released the presentation titled, “Mass spectrometry imaging for the characterization of 3D microtissues”, which was presented by Dr. Erin Seeley of Protea at the InSphero user group meeting held in San Francisco, California on October 24, 2014. The presentation can be found through the following link.
The presentation was featured in the oncology session of the InSphero user group meeting and is the first publicly released data from the collaboration between Protea and InSphero. The presentation highlights Protea’s protein and lipid mass spectrometry imaging data of InSphero’s 3D microtissues and includes data from supporting modalities such as protein and lipid profiling via mass spectrometry and bioinformatics pathway analysis. Dr. Seeley will be presenting additional data from the collaboration at the November 20, 2014 InSphero user group meeting that is being held in Boston, Massachusetts.
“The data presented by Dr. Seeley is very exciting as it highlights the capabilities of Protea’s scientific team and the multiple technological capabilities we have assembled, which we feel complement one another”, stated Steve O’Loughlin, Protea’s Vice President, Corporate Finance and Development. “We are pleased with the progress we have made with InSphero through this collaboration and look forward to presenting additional data at the next user group meeting in Boston while continuing to progress towards commercial opportunities through the combination of our respective technologies.”
Dr. Randy Strube, Director of Global Marketing for InSphero, was excited to see the data generated from 3D tumor microtissues, stating “It not only meant initial protocols for processing 3D microtissues were successfully established, but were also capable of identifying many molecules we would expect to see in tumor tissues. I think attendees at the user group meeting got a feel for the combined power of the two technologies, and the types of questions they can help answer.”
For more information about InSphero, visit www.insphero.com.
InSphero is a leading supplier of organotypic, biological in vitro 3D microtissues for highly predictive drug testing. The company, headquartered in Zurich, Switzerland, with subsidiaries in the USA and in Germany, currently counts all of the top ten global pharmaceutical and cosmetics companies as customers. InSphero 3D Insight™ Microtissues enable more biologically relevant in vitro applications in efficacy and toxicology. The spin-off company of the Swiss Federal Institute of Technology (ETH) Zurich and the University Zurich has been recognized for its scientific and commercial achievements with a number of national and international awards, including being named the #1 Swiss Startup for 2014. InSphero is certified to the ISO 9001:2008 standard for its Quality Management System.
Follow us on and www.insphero.com
About Protea Biosciences Group, Inc.
Protea (OTCQB:PRGB) is a molecular information company providing innovative bioanalytical solutions to the pharmaceutical, agricultural, and life science industries. Protea has developed a new, fully automated, molecular information technology platform, known as “LAESI” (Laser Ablation Electrospray Ionization), that enables the direct analysis of molecules without the need for sample preparation. Large molecular datasets are generated on native biological samples that can also be visually displayed as 2D and 3D images. Protea maintains its own laboratory facilities where services are provided to its clients, using LAESI and complementary technologies and expertise.
Protea and LAESI are registered trademarks of Protea Biosciences Group, Inc.
This press release may contain certain statements relating to future results. These statements are not historical facts, but instead represent only the company’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the company’s control. It is possible that the company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the company and its business, including factors that potentially could materially affect the company’s financial results, are contained in the company’s filings with the Securities and Exchange Commission. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.